-
-
28/02/2023 — Laevoroc Immunology Announces FDA Orphan Drug Designation Granted to LR 09, a Novel Metabolic Immune Checkpoint Inhibitor for the Treatment of Leukemia Relapse after Allogeneic Stem Cell Transplant
The Orphan Drug Designation underscores the significant unmet medical need and will grant LR 09 seven-year marketing exclusivity following drug approval by the FDA Zug, Switzerland, 28 February 2023: Laevoroc…
-
8/12/2022 — Laevoroc Oncology Announces Publication Identifying Purine Nucleoside Phosphorylase (PNP) as a Novel Metabolic Immune Checkpoint
UCLA data in the Journal of Clinical Investigation supports LR09 drug development as a metabolic immune checkpoint inhibitor for the treatment of leukemia Zug, Switzerland, 8 December 2022: Laevoroc Oncology…
-
18/03/2022 — Laevoroc Oncology Announces Evolution of Former Subsidiary into Joint Venture with Lipomed AG
Laevoroc Chemotherapy will develop a new oral gemcitabine prodrug, LR 06B, aiming to make a positive impact on health equity and quality of care for cancer patients around the world…
-
07/07/2021 — Laevoroc Oncology Unveils Immunology Subsidiary with CSO Shanta Bantia to Develop PNP Inhibitor for Eradication of Relapsed Leukemia
Laevoroc Oncology Unveils Immunology Subsidiary with CSO Shanta Bantia to Develop PNP Inhibitor for Eradication of Relapsed Leukemia Laevoroc Immunology formed to focus on development of a highly potent Purine…
-
24/05/2021 — Laevoroc Oncology Launches With Three-Pronged Strategy
In Vivo interview with our CEO, Thomas Mehrling, where he presented Laevoroc Oncology’s three-pronged strategy to off-set risk and provide greater choice to future partners in supporting Laevoroc’s development of…
-
11/05/2021 — Laevoroc Oncology Emerges from Stealth Mode Announcing Seed Financing and Acquisition of Worldwide Patents to Oral Gemcitabine Prodrug
Zug, Switzerland, 11 May 2021: Laevoroc Oncology (‘Laevoroc’ or ‘the company’), a privately owned, Swiss oncology development group of companies, launched today announcing successful completion of seed financing with private…
